Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 288.81 Billion KRW | 8.5% |
| 2022 | 266.18 Billion KRW | 6.39% |
| 2021 | 250.18 Billion KRW | -18.91% |
| 2020 | 308.53 Billion KRW | -5.57% |
| 2019 | 326.72 Billion KRW | 31.87% |
| 2018 | 247.75 Billion KRW | 6.73% |
| 2017 | 232.12 Billion KRW | 21.93% |
| 2016 | 190.38 Billion KRW | 20.39% |
| 2015 | 158.14 Billion KRW | 18.84% |
| 2014 | 133.06 Billion KRW | 25.78% |
| 2013 | 105.79 Billion KRW | -9.16% |
| 2012 | 116.46 Billion KRW | 7.59% |
| 2011 | 108.24 Billion KRW | -7.23% |
| 2010 | 116.67 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 291.13 Billion KRW | 2.74% |
| 2024 Q1 | 283.36 Billion KRW | -1.89% |
| 2023 Q4 | 288.81 Billion KRW | -5.63% |
| 2023 Q1 | 291.6 Billion KRW | 9.55% |
| 2023 FY | 288.81 Billion KRW | 8.5% |
| 2023 Q3 | 306.05 Billion KRW | -0.9% |
| 2023 Q2 | 308.84 Billion KRW | 5.91% |
| 2022 Q4 | 266.18 Billion KRW | 2.77% |
| 2022 FY | 266.18 Billion KRW | 6.39% |
| 2022 Q1 | 250.6 Billion KRW | 0.17% |
| 2022 Q2 | 256.83 Billion KRW | 2.49% |
| 2022 Q3 | 259.01 Billion KRW | 0.85% |
| 2021 Q2 | 294.53 Billion KRW | -2.68% |
| 2021 Q1 | 302.65 Billion KRW | -1.91% |
| 2021 Q3 | 283.9 Billion KRW | -3.61% |
| 2021 FY | 250.18 Billion KRW | -18.91% |
| 2021 Q4 | 250.18 Billion KRW | -11.87% |
| 2020 Q3 | 309.83 Billion KRW | -7.97% |
| 2020 Q2 | 336.66 Billion KRW | 6.04% |
| 2020 FY | 308.53 Billion KRW | -5.57% |
| 2020 Q1 | 317.49 Billion KRW | -2.83% |
| 2020 Q4 | 308.53 Billion KRW | -0.42% |
| 2019 Q2 | 293.42 Billion KRW | 7.37% |
| 2019 FY | 326.72 Billion KRW | 31.87% |
| 2019 Q4 | 326.72 Billion KRW | 2.84% |
| 2019 Q3 | 317.69 Billion KRW | 8.27% |
| 2019 Q1 | 273.28 Billion KRW | 10.3% |
| 2018 Q4 | 247.75 Billion KRW | -11.04% |
| 2018 Q3 | 278.51 Billion KRW | 2.28% |
| 2018 Q2 | 272.3 Billion KRW | 10.72% |
| 2018 FY | 247.75 Billion KRW | 6.73% |
| 2018 Q1 | 245.94 Billion KRW | 5.95% |
| 2017 Q4 | 232.12 Billion KRW | 7.15% |
| 2017 FY | 232.12 Billion KRW | 21.93% |
| 2017 Q2 | 196.66 Billion KRW | 3.48% |
| 2017 Q3 | 216.62 Billion KRW | 10.15% |
| 2017 Q1 | 190.05 Billion KRW | -0.17% |
| 2016 Q2 | 153.69 Billion KRW | -0.2% |
| 2016 Q4 | 190.38 Billion KRW | 11.8% |
| 2016 Q3 | 170.29 Billion KRW | 10.8% |
| 2016 FY | 190.38 Billion KRW | 20.39% |
| 2016 Q1 | 154 Billion KRW | -2.62% |
| 2015 Q3 | 148.58 Billion KRW | 5.27% |
| 2015 Q1 | 130.88 Billion KRW | -1.64% |
| 2015 Q2 | 141.14 Billion KRW | 7.85% |
| 2015 FY | 158.14 Billion KRW | 18.84% |
| 2015 Q4 | 158.14 Billion KRW | 6.43% |
| 2014 Q1 | 107.32 Billion KRW | 1.45% |
| 2014 FY | 133.06 Billion KRW | 25.78% |
| 2014 Q2 | 109.99 Billion KRW | 2.48% |
| 2014 Q4 | 133.06 Billion KRW | 9.04% |
| 2014 Q3 | 122.03 Billion KRW | 10.95% |
| 2013 Q4 | 105.79 Billion KRW | -0.4% |
| 2013 Q2 | 113.67 Billion KRW | -1.26% |
| 2013 FY | 105.79 Billion KRW | -9.16% |
| 2013 Q1 | 115.13 Billion KRW | -1.14% |
| 2013 Q3 | 106.21 Billion KRW | -6.56% |
| 2012 FY | 116.46 Billion KRW | 7.59% |
| 2012 Q2 | 102.18 Billion KRW | -6.14% |
| 2012 Q3 | 112.5 Billion KRW | 10.1% |
| 2012 Q4 | 116.46 Billion KRW | 3.52% |
| 2012 Q1 | 108.87 Billion KRW | 0.0% |
| 2011 Q2 | 73.28 Billion KRW | -11.21% |
| 2011 Q3 | 70.56 Billion KRW | -3.71% |
| 2011 FY | 108.24 Billion KRW | -7.23% |
| 2011 Q1 | 82.53 Billion KRW | 0.0% |
| 2010 Q3 | 82.14 Billion KRW | 0.0% |
| 2010 FY | 116.67 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -554.133% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | -145.064% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -216.799% |
| HANDOK Inc. | 94.46 Billion KRW | -205.738% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -1259.565% |
| Yuhan Corporation | 284.75 Billion KRW | -1.424% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | -148.306% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -1676.366% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -791.836% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -367.906% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -1382.841% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -853.802% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -497.373% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -554.133% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -824.477% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -721.044% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -500.093% |
| JW Holdings Corporation | 147.58 Billion KRW | -95.687% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -241.293% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | -10.474% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -172.231% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -435.601% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -969.76% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -788.346% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | -163.113% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -554.133% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | -53.101% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | -19.569% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -172.231% |
| Yuhan Corporation | 284.75 Billion KRW | -1.424% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | -130.534% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -365.929% |
| Suheung Co., Ltd. | 259.84 Billion KRW | -11.15% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -172.231% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -262.819% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -487.712% |
| CKD Bio Corp. | 69.08 Billion KRW | -318.072% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | -174.857% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -308.522% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -434.267% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -435.601% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | -48.288% |
| Boryung Corporation | 189.8 Billion KRW | -52.163% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -408.19% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -367.906% |
| JW Lifescience Corporation | 23.39 Billion KRW | -1134.32% |